: iStockAnalyst.com Symbols Feed

The Week in Review: Major Investments

Sun, 08 Nov 2009 01:33:43 GMT

Novartis made a five-year, $1 billion China commitment, building up its Shanghai R&D center and marketing efforts; Novartis will also spend $250 million to expand its global technical center in Changshu, and pay $125 million to buy a 85% stake in vaccine maker Zhejiang Tianyuan; Roche opened a new $500 million biologics manufacturing facility in Singapore; Microbix and Hunan Biopharmaceutical Co. will construct a $200 million flu vaccine facility;[More...]

Biostar Raises $3.6 Million

Fri, 06 Nov 2009 17:26:18 GMT

Biostar Pharmaceuticals has completed a private placement that raised $3.6 million in new capital. Biostar will use the proceeds to complete its new raw materials processing facility. By taking its raw material production in house, Biostar will lower costs and ensure its product quality. Biostar plans to sell excess raw materials to other pharmaceutical companies in the Shaanxi province.[More...]

Bulls Back On Track?

Fri, 06 Nov 2009 16:21:18 GMT

Good morning. With chants of "Dow 10K… Dow 10K" once again rising from the streets at the corner of Broad and Wall yesterday, it is easy to believe that the bulls are back on track and that we'll soon be looking at new highs for the stock market. And when reviewing the data inputs to yesterday's 204 point romp, it is also easy to don the Dow10K hat once again and join in on the celebration.[More...]

Ford's Main Problem: The UAW's Crippling Job Classifications And Work Rules

Fri, 06 Nov 2009 13:52:50 GMT

Ford's 2,215 page 2007 master contract with the UAW 1941 UAW-Ford contract[More...]

Your Kind of Day?

Thu, 05 Nov 2009 19:06:48 GMT

As a rule, I try not to read too terribly much into a "Fed Day" as there is usually a big batch of volatility that may or may not mean much of anything come the dawn of the next day. Maybe, it's just me. Or maybe there are others that find themselves inclined to simply stand aside and watch the nuttiness from the sidelines on "Fed Days." But in any event, the volatility after a Fed announcement, while fun to watch, may not be telling as to what to expect in the future.[More...]

The Dollar-Proof Portfolio

Thu, 05 Nov 2009 17:31:14 GMT

Don't put off this important piece of the financial-planning process.[More...]

What Investors Should Look for In Today’s Fed Statement

Wed, 04 Nov 2009 13:04:24 GMT

In its continuing efforts to nurture the fragile economic recovery, the U.S. Federal Reserve is widely expected to leave interest rates at record lows when it concludes its meeting today (Wednesday).[More...]

Are Discount Brokers Shares Worth Owning?

Wed, 04 Nov 2009 01:28:03 GMT

The third quarter was a favorable one for the longs. Except for a few short-lived, minor pullbacks stock prices moved higher through the quarter. Stock price volatility declined, takeover activity rose, and risk appetite improved to help the S&P gain 15%.[More...]

Technology Rises And Buying Facebook

Tue, 03 Nov 2009 16:54:11 GMT

Technology stocks have done well this year. The Technology Select Sector SPDR (XLK) bottomed out in March and by late October was up more than 60%. Tech has performed better than any other sector year-to-date – up 33.7% as of Friday’s close.[More...]

Buffett Gets His Cheque Book Out

Tue, 03 Nov 2009 16:17:34 GMT

Given the slew of positive economic data Monday you might have been forgiven for expecting a decent rebound in risk assets. There was a rebound of sorts in early New York trading, with the Dow up close to 150 points at one stage.[More...]

Earnings roundup: CommVault, Alcon

Wed, 28 Oct 2009 22:48:00 GMT

Among the earnings stories for Wednesday, Oct. 28, from AP Financial News:
OCEANPORT, N.J. (AP) - CommVault Systems Inc. reported a flat fiscal second-quarter profit as rising operating expenses and revenue costs overshadowed an increase in sales.
NEW YORK (AP) - Eye drug maker Alcon Inc. said its profit fell 18 percent in the third quarter compared with a year ago, when it received a large tax benefit.

[More...]

QLT Announces Third Quarter Results for 2009

Tue, 27 Oct 2009 11:48:00 GMT

QLT SEPARATELY ANNOUNCES SHARE REPURCHASE PROGRAM
VANCOUVER, Oct. 27 /CNW/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today reported financial results for the third quarter ended September 30, 2009.
For the third quarter and nine months ended September 30, 2009, QLT is reporting the results of our divested QLT USA business as one line item called Income from Discontinued Operations on our statements of operations.

[More...]

UPI NewsTrack TopNews

Sat, 24 Oct 2009 17:12:00 GMT

UPI NewsTrack TopNews[More...]

UPI NewsTrack TopNews

Sat, 24 Oct 2009 12:29:00 GMT

UPI NewsTrack TopNews[More...]

CDC: 16 million flu vaccine doses shipped

Sat, 24 Oct 2009 12:07:00 GMT

CDC: 16 million flu vaccine doses shipped[More...]

Chinese Bank Plans Total Acquisition of ACL Stock

Thu, 01 Oct 2009 20:47:00 GMT

Oct. 1--Industrial and Commercial Bank of China will likely acquire all shares in Thailand's ACL Bank after completing a share sale agreement with a major shareholder.
Bangkok Bank yesterday announced that it had agreed to sell its entire 19.26 percent stake in ACL Bank to ICBC, the world's largest bank in terms of total assets, at 11.50 baht per share.
The Chinese bank will make a conditional tender offer to all ACL shareholders at the same price.

[More...]

UPI NewsTrack Health and Science News

Tue, 15 Sep 2009 21:46:00 GMT

UPI NewsTrack Health and Science News[More...]

FDA approves four H1N1 vaccines

Tue, 15 Sep 2009 19:50:00 GMT

FDA approves four H1N1 vaccines[More...]

One-dose H1N1 vaccine may be on the way

Fri, 04 Sep 2009 04:22:00 GMT

One-dose H1N1 vaccine may be on the way[More...]

Canada studies asthma drug Xolair risks

Thu, 13 Aug 2009 16:32:00 GMT

Canada studies asthma drug Xolair risks[More...]

Bernhard Hampl, Ph.D. Elected to Serve As Executive Chairman of the Board of Directors of Fresenius Kabi Pharmaceuticals Holding, Inc.

Tue, 03 Nov 2009 04:47:00 GMT

Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ), which acquired APP Pharmaceuticals, Inc., September 10, 2008, today announced the election of Bernhard Hampl, Ph.D. to its Board of Directors effective November 1, 2009.
Dr. Hampl, also named as Executive Chairman of the Board, succeeds current Chairman Dr. Ulf M. Schneider.
I am pleased to be joining the Board of Fresenius Kabi Pharmaceuticals Holding and look forward to using my experience to expand APP's pipeline, while exploring new opportunities that will position it for future growth," said Dr. Hampl.

[More...]

Alcon Posts 5.9 Percent Sales Growth for Third Quarter

Tue, 27 Oct 2009 22:50:00 GMT

Alcon, Inc. (NYSE:ACL) reported global sales rose 5.9 percent to $1,614 million for the third quarter of 2009, or a 9.0 percent increase excluding the impact of foreign exchange fluctuations.
Excluding the impact of a $240 million tax benefit related to the refractive product line in 2008 and the impact of continuing expenses related to the first quarter 2009 reduction in force, adjusted net earnings for the third quarter 2009 would have grown 33.3 percent compared to non-GAAP adjusted net earnings for the third quarter of 2008.
These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by our forward-looking statements.

[More...]

RidgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on PCP, NVS, SPR, MUR, PG and OSK

Tue, 27 Oct 2009 11:10:00 GMT

RidgewaterEquity.com inspires to bring the best from the internet under one roof, providing you with a one click option to view what the market, researchers and financial pundits worldwide have to say about any particular large cap stocks in any given financial environment.
Once you sign up as a free member you will have free unlimited access to all our reports, research tools and more.
We have recently begun in-depth analysis of the following equities & their respective sectors:

[More...]

Synergetics USA, Inc. Announces Stay of Alcon Patent and Trademark Infringement Lawsuit

Thu, 24 Sep 2009 20:50:00 GMT

Synergetics USA, Inc. (NASDAQ: SURG), a leading medical device company that designs, manufactures, and markets innovative microsurgical instruments and other devices, today announced that the lawsuit filed by Alcon Research, Ltd. against the Company in the Northern District of Texas, Case No.
This lawsuit alleges infringement of United States Patents No.
The PTO has stated in its Ex Parte Re-examination Filing Data as of June 30, 2009, an average re-examination by the PTO takes approximately 25 months to complete.

[More...]

Novus Energy Inc. grants performance warrants and options

Fri, 04 Sep 2009 17:03:00 GMT

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE U.S./ (TSX Venture Exchange: "NVS")[More...]

NovaBay Pharmaceuticals Announces the Closing of Its $2.45 Million Registered Direct Offering of Common Stock and Warrants

Wed, 26 Aug 2009 21:49:00 GMT

Pharmaceuticals, Inc. (NYSE Amex: NBY) announced today that it has closed its previously announced registered direct offering of 1,225,000 units, with each unit consisting of (i) one share of the NovaBay common stock, par value $0.01 per share, and (ii) one warrant to purchase one share of NovaBay common stock.
The purchase price for each unit was $2.00.
Maxim Group LLC served as placement agent for the offering.

[More...]

Endo Pharmaceuticals to Partner With ProStrakan to Commercialize FORTESTA(TM) in the U.S.

Wed, 26 Aug 2009 13:46:00 GMT

CHADDS FORD, Pa., Aug. 26 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it has signed an agreement with U.K.-based ProStrakan Group plc (LSE: PSK) for the exclusive right to commercialize FORTESTA(TM) (testosterone gel) 2 percent in the United States.
Under the terms of the agreement, Endo Pharmaceuticals has agreed to make an upfront payment to ProStrakan of $10 million, with the potential for up to $40 million more in milestone payments by the end of 2010 for regulatory approval and the achievement of certain commercial milestones.
ProStrakan will exclusively supply FORTESTA to Endo Pharmaceuticals in the U.S. for an undisclosed supply price.

[More...]

Endo Pharmaceuticals Announces Cash Tender Offer for Any and All Outstanding Ledgemont PhaRMA(SM) Secured 16% Notes

Wed, 26 Aug 2009 11:50:00 GMT

CHADDS FORD, Pa., Aug. 26 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals announced today the commencement of a cash tender offer by its wholly-owned subsidiary, Endo Pharmaceuticals Solutions Inc., for any and all outstanding Ledgemont PhaRMA(SM) Secured 16% Notes due 2024 (the "Notes") of Ledgemont Royalty Sub LLC, Endo Pharmaceuticals Solutions Inc.'s wholly-owned subsidiary.
The purpose of the tender offer is to acquire any and all Notes to reduce the consolidated interest expense of Endo.
The tender offer is being made pursuant to an Offer to Purchase, dated August 26, 2009, and related Letter of Transmittal, dated August 26, 2009, which set forth the terms and conditions and a more detailed description of the tender offer.

[More...]

Novus Energy Inc. announces third quarter 2009 results

Tue, 25 Aug 2009 21:57:00 GMT

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE U.S./ (TSX Venture Exchange: "NVS")[More...]

Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009

Tue, 25 Aug 2009 15:45:00 GMT

Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis . PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.[More...]